CELU

1.63

5.23% -0.09

Pre-market: 1.62 -0.010 -0.61%

Celularity Inc (CELU)

Overview News Price History Option Chain Financials Discussions Forecast

Celularity Inc stock is traded at $1.63, with a volume of 49,068. It is down -5.23% in the last 24 hours and up +40.52% over the past month.

Previous Close:

$1.72

Open:

$1.66

24h Volume:

49,068

Relative Volume:

0.33

Market Cap:

$40.95M

Revenue:

$48.20M

Net Income/Loss:

$-35.05M

P/E Ratio:

-1.04

EPS:

-1.5673

Net Cash Flow:

$-13.02M

1W Performance:

-18.91%

1M Performance:

+40.52%

6M Performance:

-39.18%

1Y Performance:

-67.40%

1-Day Range:

$1.6101

$1.78

1-Week Range:

$1.6101

$2.09

52-Week Range:

$1.06

$5.69

Celularity Inc Stock (CELU) Company Profile

Name

Celularity Inc

Sector

Healthcare (1161)

Industry

Biotechnology (676)

Phone

(908) 768-2170

Address

170 PARK AVE, FLORHAM PARK

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

CELU's Discussions on Twitter

Compare CELU with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CELU Celularity Inc	1.63	40.95M	48.20M	-35.05M	-13.02M	-1.5673
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Celularity Inc Stock (CELU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jun-22-22	Initiated	H.C. Wainwright	Buy
Apr-06-22	Downgrade	Truist	Buy → Hold
Jan-28-22	Initiated	Oppenheimer	Outperform
Nov-24-21	Initiated	Morgan Stanley	Equal-Weight

View All

Celularity Inc Stock (CELU) Latest News

Mar 31, 2025

Celularity Delays Yearly Report Filing Amid Financial Challenges - TipRanks

Mar 31, 2025

Mar 22, 2025

Celularity extends debt maturity, issues stock to investor By Investing.com - Investing.com Australia

Mar 22, 2025

Mar 21, 2025

Celularity enters into standby equity purchase agreement with Ya Ii Pn -March 21, 2025 at 04:39 pm EDT - MarketScreener

Mar 21, 2025

Celularity enters into standby equity purchase agreement with Ya Ii Pn - TradingView

Mar 21, 2025

Feb 28, 2025

Celularity receives FDA TRG recommendation letters for Natalin, Acelagraft - MSN

Feb 28, 2025

CELU Stock Touches 52-Week Low at $1.29 Amid Market Challenges - Investing.com Australia

Feb 28, 2025

Feb 27, 2025

CELU Stock Touches 52-Week Low at $1.29 Amid Market Challenges By Investing.com - Investing.com South Africa

Feb 27, 2025

Feb 26, 2025

Celularity Enters Strategic Collaboration Agreement with BlueSphere Bio to Support Cell Therapy Manufacturing - Defense World

Feb 26, 2025

Feb 25, 2025

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products - The Manila Times

Feb 25, 2025

Celularity Secures Crucial FDA Pathway for Wound Care ProductsCan They Capture Share of $810M Market? - StockTitan

Feb 25, 2025

Feb 24, 2025

Celularity inks manufacturing deal with BlueSphere Bio By Investing.com - Investing.com Australia

Feb 24, 2025

Celularity inks manufacturing deal with BlueSphere Bio - Investing.com

Feb 24, 2025

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company - The Manila Times

Feb 24, 2025

Can This New Cell Therapy Manufacturing Deal Transform Celularity's Revenue Potential? - StockTitan

Feb 24, 2025

Feb 21, 2025

Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry - Simply Wall St

Feb 21, 2025

Feb 20, 2025

Celularity Inc. Extends Loan Agreements with Resorts World Inc and C.V. Starr & Co. - Defense World

Feb 20, 2025

Feb 13, 2025

SEC Form FWP filed by Celularity Inc. - Quantisnow

Feb 13, 2025

Feb 10, 2025